Plasmodium falciparum Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure

ABSTRACT The Plasmodium falciparum dihydrofolate reductase (PfDHFR) enzyme is the target of pyrimethamine, a component of the antimalarial pyrimethamine-sulfadoxine. Resistance to this drug is associated primarily with mutations in the Pfdhfr gene. The I164L mutant allele is of particular interest, because strains possessing this mutation are highly resistant to pyrimethamine and to chlorproguanil, a component of chlorproguanil-dapsone. A recent study from Malawi reported this mutation at a prevalence of 4.7% in parasites from human immunodeficiency virus-positive pregnant women by using a real-time PCR method. These observations have huge implications for the use of pyrimethamine-sulfadoxine, chlorproguanil-dapsone, and future antifolate-artemisinin combinations in Africa. It was imperative that this finding be rigorously tested. We identified a number of critical limitations in the original genotyping strategy. Using a refined and validated real-time PCR strategy, we report here that this mutation was absent in 158 isolates from Malawi and 42 isolates from Zambia collected between 2003 and 2005.

[1]  S. Meshnick,et al.  Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay. , 2008, The American journal of tropical medicine and hygiene.

[2]  M. Molyneux,et al.  Sulfadoxine-Pyrimethamine–Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi , 2008, PloS one.

[3]  R. Tahar,et al.  Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children. , 2007, Acta tropica.

[4]  A. Mazabraud,et al.  Sulfadoxine–pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Côte d'Ivoire , 2007, Annals of tropical medicine and parasitology.

[5]  M. Hoelscher,et al.  Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania , 2007, Malaria Journal.

[6]  U. d’Alessandro,et al.  HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. , 2006, The Journal of infectious diseases.

[7]  R. Tahar,et al.  Molecular epidemiology of malaria in Cameroon. XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles. , 2006, The American journal of tropical medicine and hygiene.

[8]  U. d’Alessandro,et al.  Safety and efficacy of lumefantrine-artemether (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults , 2006, Malaria Journal.

[9]  M. Molyneux,et al.  Mutations Associated with Sulfadoxine-Pyrimethamine and Chlorproguanil Resistance in Plasmodium falciparum Isolates from Blantyre, Malawi , 2005, Antimicrobial Agents and Chemotherapy.

[10]  E. Legrand,et al.  Countrywide Survey Shows Very High Prevalence of Plasmodium falciparum Multilocus Resistance Genotypes in Cambodia , 2005, Antimicrobial Agents and Chemotherapy.

[11]  E. Nduati,et al.  Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  M. Pirmohamed,et al.  Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. , 2005, British journal of clinical pharmacology.

[13]  N. White,et al.  Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  Z. Premji,et al.  Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites. , 2004, The Journal of infectious diseases.

[15]  A. Nzila,et al.  Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa , 2003, Malaria Journal.

[16]  S. Balkan,et al.  Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal Province, Sudan , 2003, Tropical medicine & international health : TM & IH.

[17]  P. Newton,et al.  A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. , 2003, Molecular biology and evolution.

[18]  E. Nduati,et al.  Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania , 2001, The Lancet.

[19]  A. Saul,et al.  Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum , 2001, Parasitology.

[20]  D. Wirth,et al.  Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. , 2000, Memorias do Instituto Oswaldo Cruz.

[21]  A. Lal,et al.  Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study , 2000, Tropical medicine & international health : TM & IH.

[22]  A. Nzila,et al.  Towards an Understanding of the Mechanism of Pyrimethamine-Sulfadoxine Resistance in Plasmodium falciparum: Genotyping of Dihydrofolate Reductase and Dihydropteroate Synthase of Kenyan Parasites , 2000, Antimicrobial Agents and Chemotherapy.

[23]  A. Nzila,et al.  The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. , 2000, The American journal of tropical medicine and hygiene.

[24]  C. Masimirembwa,et al.  Molecular epidemiology of Plasmodium falciparum antifolate resistance in Vietnam: genotyping for resistance variants of dihydropteroate synthase and dihydrofolate reductase. , 1999, International journal of antimicrobial agents.

[25]  A. Hartmann,et al.  Multiple mutation analyses in single tumor cells with improved whole genome amplification. , 1999, The American journal of pathology.

[26]  O. Doumbo,et al.  P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  O. Doumbo,et al.  Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. , 1997, The Journal of infectious diseases.

[28]  B. Pradines,et al.  Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. , 1997, The American journal of tropical medicine and hygiene.

[29]  D. Kyle,et al.  Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. , 1997, Annals of Tropical Medicine and Parasitology.

[30]  O. Doumbo,et al.  Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. , 1995, The American journal of tropical medicine and hygiene.

[31]  J. E. Hyde,et al.  The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. , 1990, Pharmacology & therapeutics.